Sirnaomics Ltd. (HK: 2257), a leading biopharmaceutical company in RNAi therapeutics, and ChemPartner, a premier pharmaceutical enterprise, have officially entered into a global non-exclusive licensing agreement. This strategic partnership will leverage the GalAhead™ delivery platform to drive innovation and development in RNAi therapeutics both in China and worldwide.

A Powerful Alliance for a New Industry Ecosystem

As the first RNAi therapeutics company to be listed in Asia, Sirnaomics is now opening its core technology platform to the industry. Dr. H. Fai Poon, CEO of Sirnaomics, remarked: "Opening our core technology platform is aimed at helping RNAi companies overcome critical challenges in target discovery and clinical translation. We look forward to collaborating with partners to identify high-quality targets and accelerate drug development, ultimately building a stronger ecosystem for the RNAi industry."

Dr. Xingquan Ma, Co-President of ChemPartner, added: "This partnership will provide companies globally with IP-secure technical support, fundamentally ensuring the safety and commercial viability of drug development and speeding up the commercialization of RNAi therapeutics."

Unlocking Key Technical Advantages

The collaboration platform offers several distinct competitive strengths:

• Strong Intellectual Property Framework: The platform features a clear and reliable IP system with solid Freedom-to-Operate (FTO) advantages, providing a secure foundation for companies to mitigate intellectual property risks during development.
• Technological Innovations: The technology enables linker-free, dual-target RNAi development, significantly enhancing drug safety. It also improves efficiency in Chemistry, Manufacturing, and Controls (CMC) processes, effectively reducing R&D costs.
• Advanced Molecular Design: The platform offers high innovation potential, capable of creating ultra-stable molecular structures. This helps overcome the current industry limitation of six-month efficacy duration, paving the way for long-acting formulations and broadening potential therapeutic applications.

Comprehensive R&D Services

This strategic cooperation combines the technical expertise and resources of both companies to establish an end-to-end service channel for RNAi drug development. The initiative is designed to empower industry innovation and propel the global RNAi therapeutics sector into a new phase of high-quality growth.

About the Companies

About ChemPartner

Founded in 2000 and headquartered in Shanghai's Zhangjiang core area,ChemPartner is an innovation-driven enterprise dedicated to integrated drug R&D and manufacturing services (CRO/CDMO).

The company operates a global network with offices, R&D centers, and production bases in Shanghai (Zhangjiang, Jinqiao, Lingang), Qidong, Chengdu, Guangzhou, Boston (USA), and Copenhagen (Denmark). ChemPartner provides integrated services spanning the entire drug development cycle—from early discovery to commercial production—for both chemical and biological drugs. It has established strategic partnerships with over 150 leading global biopharmaceutical research institutions and has served nearly 4,000 pharmaceutical and biotech companies worldwide, including almost all of the top 20 multinational pharmaceutical corporations. Involved in over 200 new drug R&D projects, ChemPartner manages thousands of R&D projects and nearly 100 IND applications annually. By 2024, the company has successfully supported clients in advancing 15 new drugs from early R&D to global market launch.

About Sirnaomics

Sirnaomics Ltd.(HK: 2257), known as Asia's "First RNAi Therapeutics Stock," is a clinical-stage global biopharmaceutical company specializing in RNA interference technology. Utilizing its dual core technology platforms and diverse pipeline, the company is at the forefront of developing RNAi therapies to drive industry growth.

Sirnaomics has two proprietary delivery platforms:

1. Polypeptide Nanoparticle (PNP) Platform: An extrahepatic delivery platform enabling precise targeting of tissues such as skin, adipose tissue, and muscle.
2. GalAhead™ Delivery Platform: A liver-targeted delivery system with clear IP and long-acting administration capabilities.

The company is also an industry leader with its innovative linker-free, dual-target RNAi technology. Sirnaomics' robust pipeline addresses oncology, local fat reduction, medical aesthetics, and cardiovascular diseases, with multiple products in clinical trials. Beyond its internal development, Sirnaomics embraces an open-collaboration strategy, integrating its technology platforms to support the broader industry and benefit patients worldwide.